PinnyPeptide

Bronchogen vs Vesugen

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Bronchogen

Bioregulators

Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue.

Peptide B

Vesugen

Bioregulators

Khavinson short peptide bioregulator targeting vascular endothelium — KED tripeptide.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists longer via gene-expression modulation

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Bronchogen effects

  • Reported restoration of bronchial epithelial function
  • Improvement in pulmonary function tests (Russian observational data)
  • Reduction in COPD/bronchitis exacerbation frequency
  • Improved dyspnea and exercise tolerance
  • Anti-inflammatory effects in bronchial tissue

Vesugen effects

  • Reported improvement in endothelial function (flow-mediated dilation)
  • Reduction in arterial stiffness measures
  • Anti-inflammatory effects on vascular endothelium
  • Modulation of vascular gene expression
  • Support of nitric oxide synthesis

Bronchogen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Occasional allergic reactions (rare)
  • Limited Western safety validation

Vesugen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Should not substitute for proven cardiovascular therapies

Bronchogen dosing ranges

Bronchial function support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Vesugen dosing ranges

Vascular health support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full Bronchogen guide → Full Vesugen guide →

Bronchogen vs Vesugen — common questions

What is the difference between Bronchogen and Vesugen?

Bronchogen: Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue. Typical dose 1,000-5,000 mcg. Vesugen: Khavinson short peptide bioregulator targeting vascular endothelium — KED tripeptide. Typical dose 1,000-5,000 mcg. Both fall under the Bioregulators category.

Can you stack Bronchogen and Vesugen?

Stacking Bronchogen with Vesugen is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Bronchogen or Vesugen?

Bronchogen is typically dosed: Once daily (SubQ) or sublingual for Bronchial function support. Vesugen is typically dosed: Once daily (SubQ) or sublingual for Vascular health support.

Are Bronchogen and Vesugen FDA approved?

Bronchogen: Not FDA approved. Vesugen: Not FDA approved.

Related peptide comparisons

bronchogen vs cardiogenbronchogen vs cartalaxbronchogen vs cortagenbronchogen vs crystagenbronchogen vs ovagenbronchogen vs pancragen

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free